Volume : 13, Issue : 06, June – 2026

Title:

RENAL DOSE ADJUSTMENT OF COMMON DRUGS-A COMPREHENSIVE CLINICAL REFERENCE FOR HEALTHCARE PROFESSIONALS-REVIEW ARTICLE

Authors :

Rahila Amjad, Syed Mohammed Hussain, Mohammed Baqtiyar Ahmed, Adiba Fathima, Dr. P. Soma Shekhar

Abstract :

Background: Chronic kidney disease (CKD) affects over 700 million people worldwide and significantly alters drug pharmacokinetics through reduced renal clearance, impaired hepatic metabolism, altered protein binding, and changed drug distribution. These changes lead to drug and metabolite accumulation when standard doses are used without adjustment, contributing to preventable adverse drug events in a population that is already highly medicated.
Objective: To provide a concise, evidence-based reference guide for renal dose adjustment of commonly prescribed drugs across five therapeutic classes — antibiotics, cardiovascular agents, antidiabetics, analgesics, and miscellaneous drugs — stratified by eGFR and dialysis status.
Methods: Dosing recommendations were compiled from authoritative sources including KDIGO 2022 CKD Guidelines, BNF 85, UpToDate, Micromedex, and Drug Prescribing in Renal Failure (Aronoff et al.). Drugs were selected based on clinical prevalence and the degree of renal adjustment required, stratified across eGFR bands of 30–59, 10–29, and <10 mL/min/1.73m² including haemodialysis.
Results: Over 60 drugs are presented with eGFR-stratified recommendations. Key findings: NSAIDs are contraindicated in significant CKD; nitrofurantoin is ineffective and toxic below eGFR 45; metformin is contraindicated below eGFR 30; apixaban is the preferred DOAC in advanced CKD; fentanyl is the opioid of choice in ESRD; and gabapentin require strict dose reduction to prevent neurotoxicity. TDM is mandatory for vancomycin, aminoglycosides, digoxin, and lithium.
Conclusion: Systematic eGFR-guided dose adjustment is essential for safe prescribing in CKD. This guide provides a practical reference framework to support clinicians across all settings in making appropriate medication decisions throughout the full spectrum of renal impairment.

Cite This Article: